Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to $122.0 million.

  • Aytu Biopharma's Liabilities and Shareholders Equity rose 496.7% to $122.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $495.4 million, marking a year-over-year increase of 341.32%. This contributed to the annual value of $124.2 million for FY2025, which is 515.01% up from last year.
  • According to the latest figures from Q4 2025, Aytu Biopharma's Liabilities and Shareholders Equity is $122.0 million, which was up 496.7% from $125.0 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Liabilities and Shareholders Equity ranged from a high of $271.6 million in Q1 2021 and a low of $115.8 million during Q3 2024
  • In the last 5 years, Aytu Biopharma's Liabilities and Shareholders Equity had a median value of $134.7 million in 2023 and averaged $155.4 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 7330.73% in 2021, then crashed by 4819.74% in 2022.
  • Quarter analysis of 5 years shows Aytu Biopharma's Liabilities and Shareholders Equity stood at $223.8 million in 2021, then plummeted by 36.81% to $141.4 million in 2022, then decreased by 7.2% to $131.2 million in 2023, then dropped by 11.45% to $116.2 million in 2024, then increased by 4.97% to $122.0 million in 2025.
  • Its last three reported values are $122.0 million in Q4 2025, $125.0 million for Q3 2025, and $124.2 million during Q2 2025.